| Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer | 09/16 08:00 | globenewswire.com |
| Immutep Quarterly Activities Report Q4 FY24 | 07/31 08:00 | globenewswire.com |
| Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals | 07/15 09:42 | zacks.com |
| Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression | 07/11 18:40 | globenewswire.com |
| Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results | 07/03 08:00 | globenewswire.com |
| Prima BioMed (IMMP) Loses -34.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner | 06/28 10:35 | zacks.com |
| Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer | 06/25 08:00 | globenewswire.com |
| Immutep successfully completes institutional placement and institutional component of entitlement offer | 06/05 06:00 | globenewswire.com |
| Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial | 06/02 20:38 | globenewswire.com |
| Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024 | 05/15 08:00 | globenewswire.com |